Applications of AI in Drug Discovery
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Applications of AI in Drug Discovery

Willie Martin, Director, Discovery Process, Alkermes

Willie Martin, Director, Discovery Process, Alkermes

Drug design software using machine learning and deep learning features aids in the discovery of new molecular targets.

The primary goal of drug discovery is to find treatments that can prevent and treat the condition in question. Metabolomics has provided several new insights into medical research. The majority of the medications are made up of small chemically synthesized molecules. These bind to the disordered molecule's target molecule. Moreover, this target molecule is almost always a protein. The identification of these molecules, on the other hand, has historically relied on the study of massive library screens. It was also followed by the detection of a possible chemical and additional testing.

Artificial Intelligence Application in Drug Discovery

Drug Repurposing

Drug repurposing also benefits from the identification of molecular drug interactions. Drugs not only engage with the target molecules but also with other molecules. As a result, existing drugs can be used to treat diseases that have no cure. Drug design software using machine learning and deep learning features aids in the discovery of new molecular targets. Furthermore, examining the drug's interactions with off-target molecules aids in the discovery of new possibilities. It also serves as a link between drug research and implementation in clinical practice.

Clinical Trials

Clinical studies consume a significant amount of time during the drug development process. Manual data analysis and monitoring take time. Furthermore, there is the possibility of human error. As a result, medication failure may occur. Artificial Intelligence (AI) algorithms can process large amounts of data while also providing reliable findings in a short amount of time. Clinical trial costs can be reduced thanks to artificial intelligence. Furthermore, it improves patient compliance. Clinical trials with AI ensure that drug effects are quickly identified. Moreover, it supports treatments with scientific proof.

Target Identification

Identification of molecules such as genes and proteins is included in the definition of molecular target identification. AI and machine learning-based drug discovery software aids in the examination of molecules. Furthermore, data mining tools for drug discovery aids in target prediction and prioritization.

Researchers have benefited from AI's assistance in analyzing massive amounts of data. Furthermore, drug design software has allowed researchers to extract information from massive datasets. Previously, AI software for drug development was limited to DNA and RNA analysis. Now, drug discovery software may use computer vision to analyze proteins further and categorize molecules.

See Also :- Top Manufacturing Technology Solution Companies
 

Weekly Brief

Read Also

Raising Capital For Early Stage Biotech Start-Ups

Raising Capital For Early Stage Biotech Start-Ups

John Kurek, Investment Manager, Uniseed
The Ever-Evolving Challenges in Drug Development and Manufacturing

The Ever-Evolving Challenges in Drug Development and Manufacturing

Kimberly Paris, SVP & Chief Compliance Officer, Quotient Sciences
Rudiments of an Effective Compliance Program

Rudiments of an Effective Compliance Program

Jeffery Williams, Chief Compliance Officer, Zoetis Inc.
How companies are supporting the genomic medicine evolution

How companies are supporting the genomic medicine evolution

Demaris Mills, President, Integrated DNA Technologies
How SoundGear Technology is Preventing a Problem in Human Health

How SoundGear Technology is Preventing a Problem in Human Health

Achin Bhowmik, Ph.D., Starkey’s Chief Technology Officer and Executive Vice President of Engineering
The challenges of bringing phytocannabinoid plant-based medicines to market.

The challenges of bringing phytocannabinoid plant-based medicines to market.

Ron Lipsky, Vice President, Business Development & International Relations at MGC Pharmaceuticals, Ltd.